Transfusion dependent patients with myelodysplastic syndrome (n=12,990, 13 studies).
Iron chelator therapy (n=1999).
No iron chelator therapy (n=10991).
Patients with secondary iron overload had a longer overall survival. Further subgroup analysis revealed a longer leukaemia free survival (LFS) in MDS patients receiving iron chelators than in MDS patients not receiving iron chelators and in patients with lower-risk MDS. Subgroup analysis of Deferasirox (DFX) showed that compared with patients not treated with iron chelators, the group receiving DFX monotherapy had significantly increased overall survival. The occurrence of cardiac adverse eventss was significantly reduced by iron chelator therapy.